TNFRSF9 and Miyoshi myopathy: Another subset of MM cases harbors a lower number of infiltrating immune cells in the BM, which could benefit from the use of co-stimulatory molecules such as Cd137 monoclonal antibodies, or from bi-specific T cell engagers such as BCMAxCD3 monoclonal antibodies44,49,50.